NUVL
Nuvalent Inc-A
NASDAQ · Biotechnology
$103.59
+2.69 (+2.67%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.56B | 1.45B | 1.21B |
| Net Income | -302,764,100 | -377,638,036 | -264,320,064 |
| EPS | — | — | — |
| Profit Margin | -19.4% | -26.0% | -21.8% |
| Rev Growth | +10.6% | +5.5% | +20.0% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 3.27B | 3.00B | 2.91B |
| Total Equity | 4.78B | 4.59B | 5.01B |
| D/E Ratio | 0.68 | 0.65 | 0.58 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | -533,448,597 | -500,050,490 | -459,692,337 |
| Free Cash Flow | -391,442,676 | -279,670,611 | -274,115,194 |